Open AccessPregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
Author(s) -
Ralf Gold,
Dusan Stefoski,
Krzysztof Selmaj,
Eva Havrdová,
Christopher Hurst,
Joan Holman,
Belén Tornesi,
Surekha S. Akella,
Peter McCroskery
Publication year - 2016
Publication title -
neurology and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.296
H-Index - 19
eISSN - 2193-8253
pISSN - 2193-6536
DOI - 10.1007/s40120-016-0048-2
Subject(s) - daclizumab , medicine , pregnancy , obstetrics , population , gynecology , transplantation , tacrolimus , environmental health , biology , genetics
Multiple sclerosis (MS) is more common in women and can occur during childbearing years; thus, information on outcomes following exposure to MS therapy during pregnancy is important. No formal studies of daclizumab have been conducted in pregnant women. Here, we report available nonclinical and clinical data on pregnancy outcomes from the daclizumab clinical study program.